Connor, Clark & Lunn Investment Management Ltd. Lineage Cell Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 206,243 shares of LCTX stock, worth $191,805. This represents 0.0% of its overall portfolio holdings.
Number of Shares
206,243
Previous 162,683
26.78%
Holding current value
$191,805
Previous $177,000
72.32%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding LCTX
# of Institutions
124Shares Held
93.5MCall Options Held
21.4KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$38.7 Million4.66% of portfolio
-
Black Rock Inc. New York, NY8.49MShares$7.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.37MShares$7.79 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA6.25MShares$5.81 Million0.86% of portfolio
-
Defender Capital, Llc.4.97MShares$4.62 Million2.61% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $158M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...